Abstract
Objective: To identify bradykinesia as part of early morning “OFF” (EMO) episodes in people with Parkinson's disease (PD) in the United States (US) using the Personal KinetiGraph® (PKG®) continuous objective monitoring (COM) device. Bradykinesia is a primary manifestation of PD and is often used as a marker for levodopa responsiveness, with persistent bradykinesia reflecting suboptimal treatment. EMO episodes are characterized by the reemergence or worsening of symptoms that occur upon awakening, before the first levodopa dose and until its beneficial effects begin. EMO episodes can be associated with significant disability and result in a negative impact on health-related quality of life. COM systems offer an opportunity to better detect “OFF” episodes, including EMO.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
